Request Information
Home About Us Products R & D Quality Safety Contact Request Information
Our Portfolio

Our Products

Four evidence-based pharmaceutical products developed to address prevalent global health challenges.

Pharmaceutical Excipient

Sodium Glycerophosphate

It acts as an organic source of phosphorus, supporting cellular metabolism and aiding in reversing hypophosphatemia.

Application

Used in parenteral nutrition solutions, injectable buffering systems, and electrolyte replenishment formulations.

Key Benefit

Ultra-high purity with full ICH Q3D elemental impurity compliance, suitable for sensitive injectable and IV applications.

Target Markets

  • Europe
  • United States
  • Russia

Antidiabetic API

Sitagliptin

It improves glycemic control when combined with diet and exercise, usually taken once daily. Common side effects include headache and nausea.

Application

Active pharmaceutical ingredient used in the treatment of Type 2 Diabetes Mellitus as a DPP-4 inhibitor.

Key Benefit

Complete genotoxic impurity profiling (ICH M7) and residual solvent control (ICH Q3C) for global generic drug filings.

Target Markets

  • Europe
  • United States
  • Russia

Antidiabetic API

Empagliflozin

It lowers blood sugar by causing the kidneys to remove excess glucose through urine. It also significantly reduces risks of heart failure hospitalizations, cardiovascular death, and chronic kidney disease progression.

Application

Active pharmaceutical ingredient used for Type 2 diabetes treatment and cardiovascular risk reduction.

Key Benefit

Full ICH Q3C and ICH Q3D compliance, supported by experimentally verified analytical data.

Target Markets

  • Europe
  • United States
  • Russia

Anticoagulant API

Apixaban

It works by directly inhibiting factor Xa, a clotting factor, and is commonly used for patients with nonvalvular atrial fibrillation or after hip/knee replacement surgery.

Application

A selective Factor Xa inhibitor used in direct oral anticoagulant formulations for the prevention and treatment of thromboembolic events.

Key Benefit

Comprehensive NMR, MS, and HPLC characterization, aligned with European Pharmacopoeia (EP) and USP standards.

Target Markets

  • Europe
  • United States
  • Russia